References:
1. Anonymous. KDOQI Clinical Practice Guidelines for Chronic Kidney
Disease: Evaluation, Classification, and Stratification. Part 7.
Stratification of risk for progression of kidney disease and development
of cardiovascular disease. Guideline 15. Association of chronic kidney
disease with cardiovascular disease
http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p7_risk_g15.htm
2.Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of
cardiovascular disease in chronic renal disease. Am J Kidney Dis
32:112-119, 1998
3.Lee
CY,
Pellikka
PA,
Shub
C,
Sinak
LJ,
Seward
JB. Hypertensive response during dobutamine stress echocardiography.
Am J Cardiol. 1997
Oct 1;80(7):970-1.
4.Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et
al. Chamber Quantification Writing Group; American Society of
Echocardiography’s Guidelines and Standards Committee; European
Association of Echocardiography. Recommendations for Cardiac Chamber
Quantification by Echocardiography in Adults: An Update from the
American Society of Echocardiography and the European Association of
Cardiovascular Imaging J Am Soc Echocardiogr. 2015 ;28:1-39
5.Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin
BP, et al. American Society of Echocardiography; European Association of
Echocardiography. American Society of Echocardiography; European
Association of Echocardiography. Echocardiographic assessment of valve
stenosis: EAE/ASE recommendations for clinical practice. J Am Soc
Echocardiogr. 2009;22:1-23.
6.Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine
RA, et al. American Society of Echocardiography. Recommendations for
evaluation of the severity of native valvular regurgitation with
two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr.
2003;16:777-802.
7. Pellikka PA, Arruda-Olson A, Chaudhry FA, Chen MH, Marshall JE,
Porter TR, Sawada SG.
Guidelines for Performance, Interpretation, and Application of Stress
Echocardiography in Ischemic Heart Disease: From the American Society of
Echocardiography. J Am Soc Echocardiogr. 2020 Jan;33(1):1-41
8. Hannan EL, Racz M, Holmes DR, King SB III., Walford G, Ambrose JA, et
al. Impact of completeness of percutaneous coronary intervention
revascularization on long-term outcomes in the stent era. Circulation.
2006;113:2406–2412.
9.Geleijnse ML, Krenning BJ, Nemes A, van Dalen BM, Soliman OI, Ten Cate
FJ, et al. Incidence, pathophysiology, and treatment of complications
during dobutamine-atropine stress echocardiography. Circulation. 2010;
121:1756-67.
10.Secknus MA, Marwick TH. Evolution of dobutamine echocardiography
protocols and indications: safety and side effects in 3,011 studies over
5 years. J Am Coll Cardiol. 1997; 29:1234-40.
11.San Román JA, Sanz-Ruiz R, Ortega JR, Pérez-Paredes M, Rollán MJ,
Muñoz AC, et al. Safety and predictors of complications with a new
accelerated dobutamine stress echocardiography protocol. J Am Soc
Echocardiogr. 2008;21:53-7.
12.Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F,
Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic
renal failure. N Engl J Med. 1992;327:1912-8.
13.Campese VM, Krol E. Neurogenic factors in renal hypertension. Curr
Hypertens Rep. 2002;4:256-60.
14.Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney
Dis. 1997; 29:2-26.’
15.Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG. Plasma renin
activity and blood pressure in terminal renal failure. N Engl J Med.
1971;285:757-62.
16.Zucchelli P, Zuccala A, Sturani A, Degli Esposti E, Ligabue A,
Santoro A, et al. Hypertension in end-stage renal failure: role of
sympathetic nervous system, sodium balance and renal pressor system.
Life Support Syst. 1983;1:101-11.
17.Vaziri ND. Effect of chronic renal failure on nitric oxide
metabolism. Am J Kidney Dis. 2001;38 (Suppl 1):S74-9.
18.Barenbrock M, Spieker C, Laske V, Baumgart P, Hoeks AP, Zidek W, et
al. Effect of long-term hemodialysis on arterial compliance in end-stage
renal failure. Nephron. 1993;65:249-53.
19.London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al.
Cardiac and arterial interactions in end-stage renal disease. Kidney
Int. 1996;50:600-8.
20.Sutliff RL, Walp ER, El-Ali AM, Elkhatib S, Lomashvili KA, O’Neill
WC. Effect of medial calcification on vascular function in uremia. Am J
Physiol Renal Physiol. 2011; 301:F78-83.
21.Baylis C. Nitric oxide deficiency in chronic kidney disease. Am J
Physiol Renal Physiol. 2008;294:F1-9.
22.Barenbrock M, Hausberg M, Kosch M, Kisters K, Hoeks AP, Rahn KH.
Effect of hyperparathyroidism on arterial distensibility in renal
transplant recipients. Kidney Int. 1998;54:210-5.
23.Gottdiener JS, Brown J, Zoltick J, Fletcher RD. Left ventricular
hypertrophy in men with normal blood pressure: relation to exaggerated
blood pressure response to exercise. Ann Intern Med. 1990;112:161-6.
24.Ha JW, Juracan EM, Mahoney DW, Oh JK, Shub C, Seward JB, et al.
Hypertensive response to exercise: a potential cause for new wall motion
abnormality in the absence of coronary artery disease. J Am Coll
Cardiol. 2002;39:323-7.
25.Sawada SG. Dobutamine stress echocardiography: Causes and approach to
false negative and false positive studies. ACC Current Journal Review
1995;4:34-38.
26.McNeill AJ, Fioretti PM, el-Said SM, Salustri A, Forster T, Roelandt
JR. Enhanced sensitivity for detection of coronary artery disease by
addition of atropine to dobutamine stress echocardiography. Am J
Cardiol. 1992;70:41-6.
27. Aggeli C, Giannopoulos G, Roussakis G, Christoforatou E, Marinos G,
Toli C, et al. Safety of myocardial flash-contrast echocardiography in
combination with dobutamine stress testing for the detection of ischemia
in 5250 studies. Heart. 2008;94:1571-7.
28.Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes.
Circulation. 2008; 118:397-409.